Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07193407 · tracked via the Priya Life Science Australia tracker
Sponsor
INOPASE Pty Ltd
Phase
Not applicable
Started
2026-02-27
Last updated
2026-05-18

Condition(s) studied

Overactive Bladder (OAB)

Investigational drug(s) / intervention(s)

Sacral Neuromodulation System

Sacral Neuromodulation System: INOPASE Sacral Neuromodulation System (INO-SNM-01) for treatment of overactive bladder.

Study summary

The goal of this clinical trial is to learn whether a new sacral neuromodulation (SNM) system (INO-SNM-01) can safely and effectively sense bladder nerve activity and provide stimulation to help manage symptoms of refractory overactive bladder in adult women aged 18-70 who have not responded to standard treatments.

The main questions it aims to answer are:

* Is there a clear relationship between bladder nerve activity and patient-reported urgency sensations?
* Can targeted stimulation based on bladder nerve activity reduce overactive bladder symptoms?
* Is the INO-SNM-01 System safe to use?

Researchers will not use a comparison group in this study. Instead, all participants will receive the investigational device to see if it works as intended.

Participants will undergo surgery to have a temporary trial lead implanted near the sacral nerve and spend up to 2 days in hospital for monitoring and testing to assess the device sensing and stimulation capabilities.

Up to 10 participants will take part in this first-in-human feasibility study at a single site in Australia.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adult female participants 18 years of age or older 2. Diagnosed with refractory overactive bladder that is resistant to behavioural therapy and/or pharmacotherapy, for at least 12 weeks 3. Experience at least 3 urgency episodes within a 24-hour period from the past 3 consecutive days (reported in a bladder diary) 4. Baseline of greater than 7 on the Overactive Bladder Symptom Score (OABSS) 5. Baseline score of greater than 12 on the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules (ICIQ-FLUTS) 6. Willing to receive SNM therapy 7. Willing to provide free and Informed consent to participate in the clinical investigation 8. Able to understand all study instructions, willing to attend all study visits, and likely to comply with all study procedures Exclusion Criteria: 1. Participants who are diagnosed with stress urinary incontinence 2. Received tibial nerve stimulation therapy within the past 3 months 3. Received treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 4. Have neurological conditions such as dementia, multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury 5. Participants who presently have, or are at high risk of urinary tract infection 6. Have uncontrolled systemic disease or comorbidities which may affect bladder function (for example diabetes, hypertension, cancer) 7. Implanted with a neurostimulator, pacemaker, or defibrillator 8. Participation in another interventional drug or device clinical trial concurrently or concluding within 30 days of screening 9. Women who are pregnant 10. Participants with known history of allergies to materials in contact with tissue for this study (i.e. adhesive dressing patch, silicone) 11. Have implanted devices that contain metallic components within 2cm of the implanted lead location 12. Any other clinical or social reason that, in the opinion of the investigator could restrict a participant's ability to successfully meet the study objectives

Primary outcome measure(s)

  • Correlation between bladder afferent nerve activity measured by the INO-SNM-01 and patient reported urgency sensation (Feeling Indicator measure) — From device implantation to the end of treatment 2 days
    Success is defined as the ability of the INO-SNM-01 device to detect an increase in nerve activity (mV) as measured by the INO-SNM-01 when the participant reports 'Urgency' on the wireless input Feeling Indicator device. The Feeling Indicator allows patients to record their urgency sensations as 'Desire to urinate', 'Loss of desire to urinate', 'Urgency' or 'Urination' in real-time throughout the test period.

Trial sites (2)

FacilityCityRegionStatus
St George Private Hospital Kogarah New South Wales Recruiting
St George Urology Kogarah New South Wales Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07193407 on ClinicalTrials.gov ↗ ← All trials in Australia